Parameswaran Venugopal

Parameswaran Venugopal, MD, is a Professor in the Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy at Rush Medical College, Rush University. He holds the prestigious Elodia Kehm Chair of Hematology and is a leading expert in lymphoma.

• Academic Rank: Professor
• Specialty: Hematology and Oncology
• Primary Focus: Lymphoma (clinical and research)
• Other Expertise: Leukemia, Myeloma, Amyloidosis, Targeted Therapies

Dr. Venugopal’s research is centered on advancing targeted therapies for hematologic malignancies, particularly in lymphoma and myeloma. His work emphasizes precision medicine approaches, including monoclonal antibodies and small molecule inhibitors, to improve patient outcomes while minimizing toxicity. He actively participates in multi-center clinical trials and translational research.

His recent publications demonstrate a strong focus on novel immunotherapies such as BTK inhibitors (acalabrutinib) and bispecific antibodies (odronextamab), as well as complications in cancer patients, including thromboembolic events in the context of infections like COVID-19. His scholarly contributions span clinical trials, case reports, and comprehensive reviews in top-tier hematology journals.

• Scientific Awards and Honors:
• Elodia Kehm Chair of Hematology

Dr. Venugopal is actively involved in clinical research and mentoring within the hematology-oncology division. He collaborates with a broad network of cancer centers across the United States, contributing to large-scale studies on treatment outcomes and prognostication in rare lymphomas. His work is supported by institutional and collaborative research funding, though specific grants are not detailed in the provided text. He is not listed as having formal PhD or Master’s students, but likely mentors fellows and junior faculty in clinical research.

He is affiliated with the Rush MD Anderson Cancer Center and sees patients at multiple locations in Chicago, Oak Park, and Lisle, IL. His clinical work is closely integrated with his academic and research responsibilities, reflecting a commitment to translational medicine.